Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Opevesostat?
Opevesostat is a small molecule commercialized by Merck, with a leading Phase III program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Data Insights
Opevesostat by Orion for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Opevesostat is under clinical development by Orion and currently in Phase III for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase...